Skip to content
A Blog by Biocon

A Blog by Biocon

  • Home
  • About Us
  • Biocon Biologics
    • Biocon Biologics @ IDF Congress 2019
      • Speaker Profiles
    • Itolizumab (ALZUMAb®) : Highly Promising Therapy for Cytokine Release Syndrome (CRS) in COVID-19
  • Healthcare
  • Innovation
  • Policy
  • Biosimilars
  • Disease Epidemiology
  • Bioconites Corner
    • Work From Home
    • Campaigns
      • Har Ghar Tiranga
      • Mother’s Day
      • Lupus Day
  • Comments Policy
  • Contact

Category: Disease Epidemiology

July 8, 2016August 8, 2016 Biocon Disease Epidemiology

Chronic Pain

Pain Management is a challenge to healthcare providers since the existing therapies have various associated cardiovascular and gastrointestinal side-effects.

Biocon Employees come together to sing our National Anthem to mark 75th Independence Day.

Itolizumab: Highly Promising Therapy for Cytokine Release Syndrome (CRS) in COVID-19

DCGI Approval for emergency use of Itolizumab in treatment of Covid-19

Biocon Biologics on Twitter

My Tweets

Biocon Biologics on Facebook

Biocon Biologics on Facebook

Biocon on Twitter

My Tweets

Search

Biocon Limited

20th KM, Hosur Road,
Electronic City,
Bangalore, India - 560 100
Email: contact.us@biocon.com
+91 80 2808 2808 / 91 80 4014 4014

Social

  • View bioconlimited’s profile on Facebook
  • View Bioconlimited’s profile on Twitter
  • View bioconlimited’s profile on YouTube

Archives

DISCLAIMER

Please read our Disclaimer and Comments Policy before engaging on our blog!

Create a website or blog at WordPress.com
  • Follow Following
    • A Blog by Biocon
      • Join 113 other followers
    • Already have a WordPress.com account? Log in now.
    • A Blog by Biocon
    • Customize
    • Follow Following
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar